AstraZeneca’s AZD0780 cuts LDL-C by 50% in Phase IIb trial
AstraZeneca's AZD0780 has demonstrated significant efficacy in a Phase IIb trial, showing a 50.7% reduction in LDL-C after 12 ...
Clinical Trials Arena6d
ACC 2025: AZD0780 shows significant LDL-C reduction in PURSUIT Phase IIb trial
AstraZeneca’s AZD0780 is an investigational oral medication that was developed to lower low-density lipoprotein cholesterol ...
AstraZeneca says AZD0780 demonstrates significant LDL-C reduction in trial
AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...
MyChesCo on MSN14h
AstraZeneca’s AZD0780 Shows Promising Results in Cholesterol-Lowering Clinical Trial
New data from the PURSUIT Phase IIb trial reveal AstraZeneca‘s investigational oral PCSK9 inhibitor, AZD0780, delivers ...
The Pharma Letter6d
AstraZeneca’s AZD0780 shows ‘potential to be a game changer’
Positive results from the PURSUIT Phase IIb trial of AstraZeneca’s AZD0780 have shown a statistically significant low-density ...
Pharmabiz5d
AstraZeneca’s AZD0780, a novel oral PCSK9 inhibitor, demonstrates significant LDL cholesterol reduction in PURSUIT phase IIb trial
AstraZeneca’s AZD0780, a novel oral PCSK9 inhibitor, demonstrates significant LDL cholesterol reduction in PURSUIT phase IIb trial: Cambridge, UK Wednesday, April 2, 2025, 11:00 ...
Applied Clinical Trials Online6d
Novel PCSK9 Inhibitor Achieves Significant Reduction in LDL Cholesterol Levels in Phase IIb Trial
Oral PCSK9 inhibitor, AZD0780, demonstrated a significant 50.7% reduction in LDL cholesterol levels in the Phase IIb PURSUIT ...
pharmaphorum6d
ACC25: AZ stakes its claim to the oral PCSK9 category
AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780, including a more than 50% reduction in ...